Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

CA Cancer Journal for Clinicians

Volumn 64, Issue 6, 2014, Pages 422-444

  Bianchi, Giada ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

hematopoietic stem cell transplant; immunomodulatory agents; microenvironment; molecularly targeted therapies; monoclonal gammopathy of undetermined significance; multiple myeloma; proteasome inhibitors; smoldering multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; IMMUNOLOGIC FACTOR;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; BLOOD DYSCRASIA; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC DISEASE; CLONAL EVOLUTION; CONSOLIDATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LEUKEMIA; MAINTENANCE CHEMOTHERAPY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; OVERALL SURVIVAL; PLASMACYTOMA; PRACTICE GUIDELINE; PRECANCER; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOLOGY; PROGNOSIS;

CLONAL EVOLUTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROGNOSIS; PROTEASOME INHIBITORS; PROTEIN FOLDING; SIGNAL TRANSDUCTION;

EID: 84911378158     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21252     Document Type: Review

References (177)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Factsheets: Myeloma. Bethesda, MD: National Cancer Institute; 2014.
3. Greenberg AJ, Rajkumar SV, Vachon CM,. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012; 119: 5359-5366.
4. Grass S, Preuss KD, Thome S, et al. Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood. 2011; 118: 635-637.
5. Anderson KC, Carrasco RD,. Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6: 249-274.
6. Hauser AE, Muehlinghaus G, Manz RA, et al. Long-lived plasma cells in immunity and inflammation. Ann N Y Acad Sci. 2003; 987: 266-269.
7. Sahota SS, Leo R, Hamblin TJ, Stevenson FK,. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood. 1997; 89: 219-226.
8. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM,. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A. 1996; 93: 13931-13936.
9. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113: 5412-5417.
10. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM,. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113: 5418-5422.
11. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24: 1121-1127.
12. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106: 812-817.
13. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110: 2586-2592.
14. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111: 785-789.
15. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV,. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013; 27: 941-946.
16. Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013; 27: 680-685.
17. Rajkumar SV, Larson D, Kyle RA,. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011; 365: 474-475.
18. Hartwell L,. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992; 71: 543-546.
19. Neri P, Bahlis NJ,. Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Exp Opin Biol Ther. 2013; 13 (suppl 1): S69-S82.
20. Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007; 11: 349-360.
21. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454: 226-231.
22. Morgan GJ, Walker BA, Davies FE,. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12: 335-348.
23. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471: 467-472.
24. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014; 28: 384-390.
25. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma [serial online]. Nat Commun. 2014; 5: 2997.
26. Darwin C,. On the Origin of Species by Means of Natural Selection, or the Preservation of Favoured Races in the Struggle for Life. London, UK: John Murray; 1859.
27. San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002; 99: 1853-1856.
28. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. J Natl Compr Canc Netw. 2011; 9: 1146-1183.
29. Lindsley H, Teller D, Noonan B, Peterson M, Mannik M,. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med. 1973; 54: 682-688.
30. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749-757.
31. Lorsbach RB, Hsi ED, Dogan A, Fend F,. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011; 136: 168-182.
32. Shortt CP, Carty F, Murray JG,. The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma. Semin Musculoskel Radiol. 2010; 14: 37-46.
33. Gleeson TG, Moriarty J, Shortt CP, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2009; 38: 225-236.
34. Mena E, Choyke P, Tan E, Landgren O, Kurdziel K,. Molecular imaging in myeloma precursor disease. Semin Hematol. 2011; 48: 22-31.
35. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118: 5989-5995.
36. Mateos MV, Lopez-Corral L, Hernandez MT, et al. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis. Blood. 2009; 114: 254-254.
37. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R,. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000; 96: 2037-2044.
38. Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study [serial online]. BMC Cancer. 2006; 6: 118.
39. Durie BG, Salmon SE,. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36: 842-854.
40. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23: 3412-3420.
41. Avet-Loiseau H,. Ultra high-risk myeloma. Hematol Am Soc Hematol Educ Program. 2010; 2010: 489-493.
42. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF,. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013; 121: 884-892.
43. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007; 92: 546-549.
44. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010; 28: 4976-4984.
45. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
46. Moreau P, Cavo M, Sonneveld P, et al. The combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014; 32: 2173-2180.
47. Hari PN, Zhang MJ, Roy V, et al. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009; 23: 1528-1534.
48. Kyle RA, Rajkumar SV,. Multiple myeloma. Blood. 2008; 111: 2962-2972.
49. Anderson KC,. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012; 30: 445-452.
50. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
51. Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol. 2006; 24: e4-e5.
52. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106: 2837-2840.
53. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010; 28: 4630-4634.
54. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012; 119: 940-948.
55. Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014; 20: 402.e1-408.e1.
56. Gertz MA, Dingli D,. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014; 124: 882-890.
57. McCarthy PL Jr, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013; 19: 1116-1123.
58. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008; 83: 614-617.
59. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
60. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010; 28: 1209-1214.
61. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011; 117: 6063-6073.
62. University Hospital, Toulous. Dana-Farber Cancer Institute, Celgene Corporation, Janssen-Cilag Ltd. Study comparing conventional dose combination RVD to high-dose treatment with ASCT in the initial myeloma up to 65 years (IFM/DFCI2009). NCT01191060. clinicaltrials.gov/show/NCT01191060. Accessed September 11, 2014.
63. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
64. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349: 2495-2502.
65. Stewart AK, Richardson PG, San-Miguel JF,. How I treat multiple myeloma in younger patients. Blood. 2009; 114: 5436-5443.
66. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376: 2075-2085.
67. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-2955.
68. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment before autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28: 4621-4629.
69. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009; 23: 1337-1341.
70. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012; 119: 4375-4382.
71. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11: 29-37.
72. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
73. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366: 1759-1769.
74. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMAâItalian Multiple Myeloma Network. J Clin Oncol. 2007; 25: 4459-4465.
75. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010; 28: 3160-3166.
76. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 1115-1123.
77. Attal M, Lauwers VC, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02. Blood. 2010; 116: 141-141.
78. Bianchi G, Richardson PG, Anderson KC,. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014; 32: 2125-2132.
79. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011; 86: 23-31.
80. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431-440.
81. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731-735.
82. Kapoor P, Kumar SK, Dispenzieri A, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013; 31: 4529-4535.
83. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013; 31: 2540-2547.
84. Dimopoulos MA, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013; 98: 784-788.
85. Rajkumar SV,. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88: 226-235.
86. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371: 906-917.
87. Orlowski RZ,. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013; 40: 634-651.
88. Basak GW, Srivastava AS, Malhotra R, Carrier E,. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009; 10: 345-346.
89. Raje N, Anderson K,. Thalidomideâa revival story. N Engl J Med. 1999; 341: 1606-1609.
90. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 1565-1571.
91. Davies F, Baz R,. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010; 24 (suppl 1): S13-S19.
92. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327: 1345-1350.
93. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343: 301-305.
94. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014; 343: 305-309.
95. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010; 24: 1934-1939.
96. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013; 121: 1968-1975.
97. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15: 333-342.
98. Adams J,. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004; 5: 417-421.
99. Goldberg AL,. Functions of the proteasome: the lysis at the end of the tunnel. Science. 1995; 268: 522-523.
100. Besche HC, Peth A, Goldberg AL,. Getting to first base in proteasome assembly. Cell. 2009; 138: 25-28.
101. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 3071-3076.
102. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20: 4420-4427.
103. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
104. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009; 144: 895-903.
105. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27: 3518-3525.
106. Kortuem KM, Stewart AK,. Carfilzomib. Blood. 2013; 121: 893-897.
107. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120: 2817-2825.
108. Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013; 27: 2351-2356.
109. Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009; 113: 3040-3049.
110. McConkey DJ, Zhu K,. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11: 164-179.
111. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003; 101: 1530-1534.
112. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010; 28: 5101-5109.
113. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012; 119: 3003-3015.
114. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012; 119: 2764-2767.
115. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108: 3289-3294.
116. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012; 119: 7-15.
117. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008; 112: 3115-3121.
118. Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014; 28: 690-693.
119. Bashey A, Perez WS, Zhang MJ, et al. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008; 14: 1118-1124.
120. Gahrton G, Svensson H, Bjorkstrand B, et al. Syngeneic transplantation in multiple myelomaâa case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999; 24: 741-745.
121. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001; 98: 934-939.
122. Armeson KE, Hill EG, Costa LJ,. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013; 48: 562-567.
123. Walter P, Ron D,. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011; 334: 1081-1086.
124. Cenci S, van Anken E, Sitia R,. Proteostenosis and plasma cell pathophysiology. Curr Opin Cell Biol. 2011; 23: 216-222.
125. Komander D, Clague MJ, Urbe S,. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009; 10: 550-563.
126. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C,. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012; 31: 2373-2388.
127. Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012; 22: 345-358.
128. Tian Z, D'Arcy P, Wang X, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014; 123: 706-716.
129. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP,. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003; 115: 727-738.
130. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012; 119: 2579-2589.
131. Yee A, Vorhees P, Bensinger WI, et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2013; 122. Abstract 3190.
132. Raje N, Vogl DT, Hari PN, et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2013; 122. Abstract 759.
133. Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature. 2002; 415: 92-96.
134. Bagratuni T, Wu P, Gonzalez, de Castro D, et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010; 116: 250-253.
135. Papandreou I, Denko NC, Olson M, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011; 117: 1311-1314.
136. Mimura N, Hideshima T, Gorgun G, et al. Targeting IRE1 alpha-XBP1 pathway is a novel therapeutic strategy in multiple myeloma. Blood. 2010; 116: 1659-1659.
137. Hartl FU, Bracher A, Hayer-Hartl M,. Molecular chaperones in protein folding and proteostasis. Nature. 2011; 475: 324-332.
138. Garcia-Carbonero R, Carnero A, Paz-Ares L,. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013; 14: e358-e369.
139. Stuhmer T, Zollinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008; 22: 1604-1612.
140. Nakashima T, Ishii T, Tagaya H, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 2010; 16: 2792-2802.
141. Harvey RD, Lonial S,. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 2007; 3: 639-647.
142. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006; 107: 4053-4062.
143. Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011; 29: 4243-4249.
144. Mitsiades CS, Ocio EM, Pandiella A, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008; 68: 5216-5225.
145. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]. PLoS One. 2009; 4: e7258.
146. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
147. Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013; 14: 1129-1140.
148. Siegel DS, Richardson P, Dimopoulos M, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma [serial online]. Blood Cancer J. 2014; 4: e182.
149. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122: 2331-2337.
150. San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013; 31: 3696-3703.
151. Richardson PG, Hungria VTM, Yoon S-S, et al. Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma [abstract]. J Clin Oncol. 2014; 32 (5S). Abstract 8510.
152. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012; 120: 1877-1887.
153. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146: 904-917.
154. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002; 1: 539-544.
155. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113: 4341-4351.
156. Hu J, Handisides DR, Van Valckenborgh E, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010; 116: 1524-1527.
157. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009; 114: 371-379.
158. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012; 30: 1953-1959.
159. de, Weers M, Tai YT, van der, Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011; 186: 1840-1848.
160. Plesner T, Arkenau T, Lokhorst H, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2013; 122. Abstract 1986.
161. Arnason J, Avigan D,. Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. Immunotherapy. 2012; 4: 1043-1051.
162. Baxter AG, Hodgkin PD,. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol. 2002; 2: 439-446.
163. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.
164. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011; 117: 393-402.
165. Rosenblatt J, Avivi I, Vasir B, et al. Blockade of PD-1 in combination with dendritic cell/myeloma fusion cell vaccination following autologous stem cell transplantation [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120. Abstract 578.
166. DiCapua Siegel DS, Moreau P, Avigan D, et al. A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol. 2014; 32 (15S). Abstract TPS3117.
167. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16: 593-602.
168. Jackson GH, Morgan GJ, Davies FE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol. 2014; 166: 109-117.
169. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer. 2010; 126: 239-246.
170. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691.
171. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010; 376: 1989-1999.
172. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23: 8580-8587.
173. Durie BG, Katz M, Crowley J,. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005; 353: 99-102; discussion 199-102.
174. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013; 31: 2347-2357.
175. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 1125-1132.
176. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22: 414-423.
177. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26: 4784-4790.